SpeeDx announced further series A funding received by new investor partners, Northpond Ventures, LP – a U.S.-based, formative stage venture capital fund with a strong science and technology driven portfolio. The funds received form part of a larger agreement that includes the addition of Northpond Ventures founder and CEO, Michael P. Rubin, M.D., Ph.D., on the SpeeDx Board of Directors.
“SpeeDx is uniquely positioned in the sexual health diagnostics space, with technology and tests that can inform treatment decisions,” said Dr. Rubin. “We are excited about the impact they are having now, in Europe and Australian markets, and we look forward to what we can achieve together with the current investors as we look to expand the offered test menu and prepare for the U.S. launch.”
Read the full press release.